Rare Daily Staff
Chiesi Farmaceutici said it has formed Chiesi Global Rare Diseases, a new business unit that will research and develop therapies for rare and ultra-rare diseases.
The unit will be based in Boston and have an initial focus on lysosomal storage, hematological, ophthalmological disorders.
“Chiesi has a long history of success in discovering, developing, and commercializing innovative therapies to address unmet needs for people living with rare diseases,” said Giacomo Chiesi, head of Chiesi Global Rare Diseases. “With the Chiesi Global Rare Diseases unit, we are taking this to an entirely new level—rededicating and strengthening our efforts to support individuals and families affected by rare diseases all around the world.”
Chiesi Group markets treatments for the lysosomal storage disorders alpha mannosidosis and nephropathic cystinosis in select markets outside the United States. The company is also building a pipeline of therapies for the treatment of lysosomal storage disorders and other rare diseases.
In 2018, Chiesi acquired U.S. rights to commercialize pegunigalsidase alfa (or PRX-102), an investigational therapy currently in development for the potential treatment of Fabry disease. PRX-102 is currently being evaluated in phase 3 clinical trials.
Photo: Giacomo Chiesi, head of Chiesi Global Rare Diseases